http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 10 Aug 2026 02:33:07 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Sobi+licenses+lacutamab+from+Innate+Pharma+in+%2475M+upfront+deal/26892993.html <p>Swedish Orphan Biovitrum AB (Nasdaq Stockholm: SOBI), known as Sobi, and Innate Pharma SA (Euronext Paris: IPH, NASDAQ: IPHA) announced a licensing partnership for lacutamab, an anti-KIR3DL2 antibody in development for cutaneous T-cell lymphoma (CTCL).</p> <p>Under the agreement, Sobi will pay Innate Pharma $75 million upon closing. Innate is eligible to receive up to an additional $40 million in near-term development milestones tied to Sézary syndrome, and up to $465 million related to a Sobi option for full development rights and future regulatory and commercial milestones. Innate will also receive tiered double-digit royalties on net sales.</p> <p>Innate will conduct the TELLOMAK-3 Phase http://www.streetinsider.com/Corporate+News/Sobi+licenses+lacutamab+from+Innate+Pharma+in+%2475M+upfront+deal/26892993.html Mon, 10 Aug 2026 02:33:07 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI http://www.streetinsider.com/Corporate+News/Sobi+licenses+lacutamab+from+Innate+Pharma+in+%2475M+upfront+deal/26892993.html <p>Swedish Orphan Biovitrum AB (Nasdaq Stockholm: SOBI), known as Sobi, and Innate Pharma SA (Euronext Paris: IPH, NASDAQ: IPHA) announced a licensing partnership for lacutamab, an anti-KIR3DL2 antibody in development for cutaneous T-cell lymphoma (CTCL).</p> <p>Under the agreement, Sobi will pay Innate Pharma $75 million upon closing. Innate is eligible to receive up to an additional $40 million in near-term development milestones tied to Sézary syndrome, and up to $465 million related to a Sobi option for full development rights and future regulatory and commercial milestones. Innate will also receive tiered double-digit royalties on net sales.</p> <p>Innate will conduct the TELLOMAK-3 Phase http://www.streetinsider.com/Corporate+News/Sobi+licenses+lacutamab+from+Innate+Pharma+in+%2475M+upfront+deal/26892993.html Mon, 10 Aug 2026 02:33:07 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI http://www.streetinsider.com/Corporate+News/Sobi+licenses+lacutamab+from+Innate+Pharma+in+%2475M+upfront+deal/26892993.html <p>Swedish Orphan Biovitrum AB (Nasdaq Stockholm: SOBI), known as Sobi, and Innate Pharma SA (Euronext Paris: IPH, NASDAQ: IPHA) announced a licensing partnership for lacutamab, an anti-KIR3DL2 antibody in development for cutaneous T-cell lymphoma (CTCL).</p> <p>Under the agreement, Sobi will pay Innate Pharma $75 million upon closing. Innate is eligible to receive up to an additional $40 million in near-term development milestones tied to Sézary syndrome, and up to $465 million related to a Sobi option for full development rights and future regulatory and commercial milestones. Innate will also receive tiered double-digit royalties on net sales.</p> <p>Innate will conduct the TELLOMAK-3 Phase http://www.streetinsider.com/Corporate+News/Sobi+licenses+lacutamab+from+Innate+Pharma+in+%2475M+upfront+deal/26892993.html Mon, 10 Aug 2026 02:33:07 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI http://www.streetinsider.com/Corporate+News/Sobi+licenses+lacutamab+from+Innate+Pharma+in+%2475M+upfront+deal/26892993.html <p>Swedish Orphan Biovitrum AB (Nasdaq Stockholm: SOBI), known as Sobi, and Innate Pharma SA (Euronext Paris: IPH, NASDAQ: IPHA) announced a licensing partnership for lacutamab, an anti-KIR3DL2 antibody in development for cutaneous T-cell lymphoma (CTCL).</p> <p>Under the agreement, Sobi will pay Innate Pharma $75 million upon closing. Innate is eligible to receive up to an additional $40 million in near-term development milestones tied to Sézary syndrome, and up to $465 million related to a Sobi option for full development rights and future regulatory and commercial milestones. Innate will also receive tiered double-digit royalties on net sales.</p> <p>Innate will conduct the TELLOMAK-3 Phase http://www.streetinsider.com/Corporate+News/Sobi+licenses+lacutamab+from+Innate+Pharma+in+%2475M+upfront+deal/26892993.html Mon, 10 Aug 2026 02:33:07 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI http://www.streetinsider.com/Corporate+News/Sobi+licenses+lacutamab+from+Innate+Pharma+in+%2475M+upfront+deal/26892993.html <p>Swedish Orphan Biovitrum AB (Nasdaq Stockholm: SOBI), known as Sobi, and Innate Pharma SA (Euronext Paris: IPH, NASDAQ: IPHA) announced a licensing partnership for lacutamab, an anti-KIR3DL2 antibody in development for cutaneous T-cell lymphoma (CTCL).</p> <p>Under the agreement, Sobi will pay Innate Pharma $75 million upon closing. Innate is eligible to receive up to an additional $40 million in near-term development milestones tied to Sézary syndrome, and up to $465 million related to a Sobi option for full development rights and future regulatory and commercial milestones. Innate will also receive tiered double-digit royalties on net sales.</p> <p>Innate will conduct the TELLOMAK-3 Phase http://www.streetinsider.com/Corporate+News/Sobi+licenses+lacutamab+from+Innate+Pharma+in+%2475M+upfront+deal/26892993.html Mon, 10 Aug 2026 02:33:07 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI http://www.streetinsider.com/Corporate+News/Sobi+licenses+lacutamab+from+Innate+Pharma+in+%2475M+upfront+deal/26892993.html <p>Swedish Orphan Biovitrum AB (Nasdaq Stockholm: SOBI), known as Sobi, and Innate Pharma SA (Euronext Paris: IPH, NASDAQ: IPHA) announced a licensing partnership for lacutamab, an anti-KIR3DL2 antibody in development for cutaneous T-cell lymphoma (CTCL).</p> <p>Under the agreement, Sobi will pay Innate Pharma $75 million upon closing. Innate is eligible to receive up to an additional $40 million in near-term development milestones tied to Sézary syndrome, and up to $465 million related to a Sobi option for full development rights and future regulatory and commercial milestones. Innate will also receive tiered double-digit royalties on net sales.</p> <p>Innate will conduct the TELLOMAK-3 Phase http://www.streetinsider.com/Corporate+News/Sobi+licenses+lacutamab+from+Innate+Pharma+in+%2475M+upfront+deal/26892993.html Mon, 10 Aug 2026 02:33:07 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI http://www.streetinsider.com/Corporate+News/Sobi+licenses+lacutamab+from+Innate+Pharma+in+%2475M+upfront+deal/26892993.html <p>Swedish Orphan Biovitrum AB (Nasdaq Stockholm: SOBI), known as Sobi, and Innate Pharma SA (Euronext Paris: IPH, NASDAQ: IPHA) announced a licensing partnership for lacutamab, an anti-KIR3DL2 antibody in development for cutaneous T-cell lymphoma (CTCL).</p> <p>Under the agreement, Sobi will pay Innate Pharma $75 million upon closing. Innate is eligible to receive up to an additional $40 million in near-term development milestones tied to Sézary syndrome, and up to $465 million related to a Sobi option for full development rights and future regulatory and commercial milestones. Innate will also receive tiered double-digit royalties on net sales.</p> <p>Innate will conduct the TELLOMAK-3 Phase http://www.streetinsider.com/Corporate+News/Sobi+licenses+lacutamab+from+Innate+Pharma+in+%2475M+upfront+deal/26892993.html Mon, 10 Aug 2026 02:33:07 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI http://www.streetinsider.com/Press+Releases/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and <span value="EuronextParis:IPH" idsrc="xmltag.org" >Innate Pharma SA</span> (<span value="ACORN:2680095202" idsrc="xmltag.org" >Euronext Paris</span>: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.</p> <p>Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in http://www.streetinsider.com/Press+Releases/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html Mon, 10 Aug 2026 02:32:00 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI SOBI http://www.streetinsider.com/Press+Releases/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and <span value="EuronextParis:IPH" idsrc="xmltag.org" >Innate Pharma SA</span> (<span value="ACORN:2680095202" idsrc="xmltag.org" >Euronext Paris</span>: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.</p> <p>Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in http://www.streetinsider.com/Press+Releases/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html Mon, 10 Aug 2026 02:32:00 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI SOBI http://www.streetinsider.com/Press+Releases/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and <span value="EuronextParis:IPH" idsrc="xmltag.org" >Innate Pharma SA</span> (<span value="ACORN:2680095202" idsrc="xmltag.org" >Euronext Paris</span>: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.</p> <p>Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in http://www.streetinsider.com/Press+Releases/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html Mon, 10 Aug 2026 02:32:00 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI SOBI http://www.streetinsider.com/Press+Releases/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and <span value="EuronextParis:IPH" idsrc="xmltag.org" >Innate Pharma SA</span> (<span value="ACORN:2680095202" idsrc="xmltag.org" >Euronext Paris</span>: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.</p> <p>Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in http://www.streetinsider.com/Press+Releases/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html Mon, 10 Aug 2026 02:32:00 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI SOBI http://www.streetinsider.com/Press+Releases/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and <span value="EuronextParis:IPH" idsrc="xmltag.org" >Innate Pharma SA</span> (<span value="ACORN:2680095202" idsrc="xmltag.org" >Euronext Paris</span>: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.</p> <p>Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in http://www.streetinsider.com/Press+Releases/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html Mon, 10 Aug 2026 02:32:00 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI SOBI http://www.streetinsider.com/Press+Releases/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and <span value="EuronextParis:IPH" idsrc="xmltag.org" >Innate Pharma SA</span> (<span value="ACORN:2680095202" idsrc="xmltag.org" >Euronext Paris</span>: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.</p> <p>Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in http://www.streetinsider.com/Press+Releases/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html Mon, 10 Aug 2026 02:32:00 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI SOBI http://www.streetinsider.com/Press+Releases/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and <span value="EuronextParis:IPH" idsrc="xmltag.org" >Innate Pharma SA</span> (<span value="ACORN:2680095202" idsrc="xmltag.org" >Euronext Paris</span>: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.</p> <p>Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in http://www.streetinsider.com/Press+Releases/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html Mon, 10 Aug 2026 02:32:00 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI SOBI http://www.streetinsider.com/Press+Releases/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and <span value="EuronextParis:IPH" idsrc="xmltag.org" >Innate Pharma SA</span> (<span value="ACORN:2680095202" idsrc="xmltag.org" >Euronext Paris</span>: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.</p> <p>Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in http://www.streetinsider.com/Press+Releases/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html Mon, 10 Aug 2026 02:32:00 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI SOBI http://www.streetinsider.com/PRNewswire/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and <span value="EuronextParis:IPH" idsrc="xmltag.org" >Innate Pharma SA</span> (<span value="ACORN:2680095202" idsrc="xmltag.org" >Euronext Paris</span>: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.</p> <p>Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in http://www.streetinsider.com/PRNewswire/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html Mon, 10 Aug 2026 02:32:00 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI SOBI http://www.streetinsider.com/PRNewswire/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and <span value="EuronextParis:IPH" idsrc="xmltag.org" >Innate Pharma SA</span> (<span value="ACORN:2680095202" idsrc="xmltag.org" >Euronext Paris</span>: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.</p> <p>Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in http://www.streetinsider.com/PRNewswire/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html Mon, 10 Aug 2026 02:32:00 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI SOBI http://www.streetinsider.com/PRNewswire/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and <span value="EuronextParis:IPH" idsrc="xmltag.org" >Innate Pharma SA</span> (<span value="ACORN:2680095202" idsrc="xmltag.org" >Euronext Paris</span>: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.</p> <p>Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in http://www.streetinsider.com/PRNewswire/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html Mon, 10 Aug 2026 02:32:00 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI SOBI http://www.streetinsider.com/PRNewswire/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and <span value="EuronextParis:IPH" idsrc="xmltag.org" >Innate Pharma SA</span> (<span value="ACORN:2680095202" idsrc="xmltag.org" >Euronext Paris</span>: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.</p> <p>Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in http://www.streetinsider.com/PRNewswire/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html Mon, 10 Aug 2026 02:32:00 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI SOBI http://www.streetinsider.com/PRNewswire/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and <span value="EuronextParis:IPH" idsrc="xmltag.org" >Innate Pharma SA</span> (<span value="ACORN:2680095202" idsrc="xmltag.org" >Euronext Paris</span>: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.</p> <p>Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in http://www.streetinsider.com/PRNewswire/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html Mon, 10 Aug 2026 02:32:00 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI SOBI http://www.streetinsider.com/PRNewswire/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and <span value="EuronextParis:IPH" idsrc="xmltag.org" >Innate Pharma SA</span> (<span value="ACORN:2680095202" idsrc="xmltag.org" >Euronext Paris</span>: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.</p> <p>Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in http://www.streetinsider.com/PRNewswire/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html Mon, 10 Aug 2026 02:32:00 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI SOBI http://www.streetinsider.com/PRNewswire/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and <span value="EuronextParis:IPH" idsrc="xmltag.org" >Innate Pharma SA</span> (<span value="ACORN:2680095202" idsrc="xmltag.org" >Euronext Paris</span>: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.</p> <p>Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in http://www.streetinsider.com/PRNewswire/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html Mon, 10 Aug 2026 02:32:00 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI SOBI http://www.streetinsider.com/PRNewswire/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/se..stholm" idsrc="xmltag.org" >STOCKHOLM</location></span>, <span class="legendSpanClass"><chron>Aug. 10, 2026</chron></span> /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and <span value="EuronextParis:IPH" idsrc="xmltag.org" >Innate Pharma SA</span> (<span value="ACORN:2680095202" idsrc="xmltag.org" >Euronext Paris</span>: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.</p> <p>Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in http://www.streetinsider.com/PRNewswire/Sobi+enters+strategic+partnership+with+Innate+Pharma+to+license+lacutamab+in+T-cell+lymphoma/26892992.html Mon, 10 Aug 2026 02:32:00 -0400 A.26800952 IPH IPHA O.00380011 O.00610222 O.00711722 SOBI SOBI http://www.streetinsider.com/Management+Changes/Sobi+CEO+Guido+Oelkers+to+depart+by+end+of+January+2027/26852346.html <p>Swedish Orphan Biovitrum AB (Nasdaq Stockholm: SOBI), known as Sobi, announced that Chief Executive Officer Guido Oelkers has informed the board of directors of his decision to step down to take a position outside the company.</p> <p>Oelkers will remain in his role until the end of January 2027 at the latest. The board said it has begun a search for a successor to ensure a structured transition.</p> <p>"On behalf of the Board, I would like to sincerely thank Guido for nearly 10 years of dedication and leadership at Sobi," said David Meek, chairman of the board of directors. "The Board has now http://www.streetinsider.com/Management+Changes/Sobi+CEO+Guido+Oelkers+to+depart+by+end+of+January+2027/26852346.html Mon, 03 Aug 2026 01:25:52 -0400 O.00610222 SOBI http://www.streetinsider.com/Management+Changes/Sobi+CEO+Guido+Oelkers+to+depart+by+end+of+January+2027/26852346.html <p>Swedish Orphan Biovitrum AB (Nasdaq Stockholm: SOBI), known as Sobi, announced that Chief Executive Officer Guido Oelkers has informed the board of directors of his decision to step down to take a position outside the company.</p> <p>Oelkers will remain in his role until the end of January 2027 at the latest. The board said it has begun a search for a successor to ensure a structured transition.</p> <p>"On behalf of the Board, I would like to sincerely thank Guido for nearly 10 years of dedication and leadership at Sobi," said David Meek, chairman of the board of directors. "The Board has now http://www.streetinsider.com/Management+Changes/Sobi+CEO+Guido+Oelkers+to+depart+by+end+of+January+2027/26852346.html Mon, 03 Aug 2026 01:25:52 -0400 O.00610222 SOBI